Overview
Mesoblast is a development-led biotechnology company whose investment story centres on regenerative medicine and a pipeline spanning several serious conditions. Its A$2.6 billion market capitalisation sits alongside A$120.3 million in trailing revenue, but the company remains loss-making, with a -47.82% profit margin and negative earnings per share. For investors, the central balance is between the potential of its treatment programmes and the clinical, commercial and financial uncertainty involved in turning them into durable growth.
Mesoblast is an Australian biotechnology company developing regenerative medicine products using mesenchymal lineage cells. Its programmes address a varied set of conditions, including inflammatory diseases, heart failure, chronic low back pain and hypoplastic left heart syndrome. The breadth of the pipeline gives the business multiple potential areas of application, but it also means its outlook is closely tied to development progress and the ability to bring treatments through clinical and commercial stages. The supplied figures show trailing revenue of A$120.3 million, with revenue growth of 3.91%; however, a -47.82% profit margin and negative earnings per share show that revenue has not translated into profitability.
Key facts
- Ticker
- MSB
- Exchange
- AU
- ISIN
- AU000000MSB8
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Currency
- AUD
- Price
- A$2.01
- Previous close
- A$1.94
- Day change
- +A$0.07 (+3.62%)
- Market cap
- 2.5B
- 52W low
- A$1.88
- 52W high
- A$3.31
Price and trend
Last price: A$2.01
- Price
- A$2.01
- 52W range
- A$1.88 – A$3.31
- 50-day SMA
- A$2.22
- 200-day SMA
- A$2.25
- Price vs 50D SMA
- -9.71%
- Price vs 200D SMA
- -10.70%
Valuation
- P/E
- 0.00
- PEG
- 0.13
- EPS
- -0.07
- Beta
- 0.86
Mesoblast has a market capitalisation of A$2.6 billion, but its negative earnings make conventional earnings-based valuation comparisons difficult to interpret. The valuation therefore rests substantially on expectations for pipeline development and future commercial potential, rather than established profitability. The supplied target price of A$3.64 is 78.27% from the last price, but that estimate should be viewed as context, not a substitute for assessing clinical progress and financial performance.
Profitability and growth
- Revenue growth
- 3.91%
- Revenue TTM
- 120.3M
- Profit margin
- -47.82%
Analyst view
Comparison uses the last price shown; targets are analyst estimates.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
- Price
- A$2.01
- Target price
- A$3.64
- Target vs last price
- 81.38% from last price
Analyst price expectations are secondary to Mesoblast’s clinical and commercial execution. The supplied target price is A$3.64, which is 78.27% from the last price of A$2.04. This is an estimate rather than a measure of the company’s ability to advance its pipeline or achieve sustained earnings.
Risks
Mesoblast’s prospects depend heavily on clinical development and the eventual regulatory and commercial progress of its treatments. Set against that pipeline potential, the supplied figures show a -47.82% profit margin and negative earnings per share, highlighting the challenge of translating development work into sustained profitability. The share price is also below its 50-day and 200-day moving averages, while its position within a broad 52-week range reflects meaningful price variability. These factors make execution and the path to durable earnings central uncertainties.
FAQ
What does Mesoblast do?
Mesoblast is an Australian biotechnology company developing regenerative medicine treatments based on specialised mesenchymal lineage cells. Its programmes target a range of inflammatory, cardiac and other conditions.
What do Mesoblast’s financial results indicate?
The supplied figures show A$120.3 million in trailing revenue and revenue growth of 3.91%, alongside a profit margin of -47.82% and negative earnings per share. The figures point to a business with revenue but substantial reported losses.
How is MSB trading relative to its recent range and moving averages?
At A$2.04, MSB is within its A$1.88–A$3.31 52-week range and below both its A$2.23 50-day and A$2.26 200-day moving averages. That provides a cautious technical backdrop, though it does not determine the company’s clinical or commercial prospects.
*This content is aimed to provide general information only, and does not take your personal objectives, financial situation or needs into account.
